-
公开(公告)号：US20190218279A1
公开(公告)日：2019-07-18
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
Patent Agency Ranking
公开(公告)号：US20210395313A1
公开(公告)日：2021-12-23
申请号：US16619874
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Essa Hu HARRINGTON , Fang-Tsao HONG , Jason C. LONG , Leslie P. MIRANDA
Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
-
公开(公告)号：US20210017261A1
公开(公告)日：2021-01-21
申请号：US16919032
申请日：2020-07-01
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20240150448A1
公开(公告)日：2024-05-09
申请号：US18545688
申请日：2023-12-19
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K2039/545 , C07K2317/34 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20220363770A1
公开(公告)日：2022-11-17
申请号：US17621189
申请日：2020-06-26
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Fernando GARCES , Mark Leo MICHAELS , Christopher MOHR , Kenneth William WALKER , Zhulun WANG , Neeraj Jagdish AGRAWAL , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Derek E. PIPER , Cen XU
Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20220195022A1
公开(公告)日：2022-06-23
申请号：US17558032
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
-
-
-
-
Search Results
6
records
(took 0.018 seconds)
